News
PROK
1.110
-3.48%
-0.040
ProKidney Corp. Reports $141.9 million in Cash and Outlines Phase 3 PROACT 1 Milestones
NASDAQ · 1d ago
Weekly Report: what happened at PROK last week (1102-1106)?
Weekly Report · 2d ago
ProKidney: The Runway Narrows Before the Pivotal Readout Arrives
Barchart · 4d ago
Weekly Report: what happened at PROK last week (1026-1030)?
Weekly Report · 11/02 10:23
ProKidney Announces At-the-Market Equity Offering Agreement
TipRanks · 10/29 21:50
ProKidney Corp. Enters $200 Million At-The-Market Offering Agreement With Jefferies
Benzinga · 10/29 21:37
ProKidney files $650M mixed securities shelf
TipRanks · 10/29 20:50
Analysts Are Bullish on Top Healthcare Stocks: Precision BioSciences (DTIL), ProKidney (PROK)
TipRanks · 10/29 08:40
ProKidney Is Maintained at Buy by Citigroup
Dow Jones · 10/28 20:57
ProKidney Price Target Cut to $8.00/Share From $10.00 by Citigroup
Dow Jones · 10/28 20:57
Citigroup Maintains Buy on ProKidney, Lowers Price Target to $8
Benzinga · 10/28 20:47
ProKidney price target lowered to $8 from $10 at Citi
TipRanks · 10/28 10:46
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Beam Therapeutics (BEAM) and ProKidney (PROK)
TipRanks · 10/28 01:31
Weekly Report: what happened at PROK last week (1019-1023)?
Weekly Report · 10/26 10:22
Weekly Report: what happened at PROK last week (1012-1016)?
Weekly Report · 10/19 10:22
Analysts Conflicted on These Healthcare Names: ProKidney (PROK) and Roivant Sciences (ROIV)
TipRanks · 10/12 12:50
Weekly Report: what happened at PROK last week (1005-1009)?
Weekly Report · 10/12 10:28
Weekly Report: what happened at PROK last week (0928-1002)?
Weekly Report · 10/05 10:28
ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026
Barchart · 10/02 08:00
Weekly Report: what happened at PROK last week (0921-0925)?
Weekly Report · 09/28 10:22
More
Webull provides a variety of real-time PROK stock news. You can receive the latest news about ProKidney through multiple platforms. This information may help you make smarter investment decisions.
About PROK
Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.